Trump UNLEASHES Psychedelics — Banned Drugs Fast-Tracked

President Trump signs executive order fast-tracking psychedelic drugs long banned as Schedule I substances, potentially revolutionizing mental health treatment for veterans while challenging decades of federal overreach.

Story Highlights

Trump signed the order on April 18, 2026, in the Oval Office with Joe Rogan and Navy SEAL Marcus Luttrell present.
FDA to expedite review of three psychedelic compounds, including ibogaine, using 1-2 month timelines.
$50 million federal funding allocated through ARPA-H to boost research and match state investments.
Right to Try pathways open immediate access for treatment-resistant patients, prioritizing veterans with PTSD.
Order directs DEA rescheduling reviews post successful Phase 3 trials, signaling shift from 1960s drug war restrictions.

Executive Order Signing Ceremony

President Donald Trump signed the executive order on April 18, 2026, during an Oval Office ceremony. Attendees included podcaster Joe Rogan, who texted Trump advocating for ibogaine research, and former Navy SEAL Marcus Luttrell representing veterans. FDA Commissioner Mary Makary announced immediate review of three psychedelic compounds designated as Breakthrough Therapy drugs. Trump described the action as historic reforms to accelerate access to promising treatments. The move addresses treatment-resistant mental illness after standard therapies fail.

Key Components of the Order

FDA National Priority Vouchers enable 1-2 month review timelines for qualifying psychedelics. The Right to Try Act provides pathways for eligible patients to access investigational drugs like ibogaine that meet basic safety standards. ARPA-H receives $50 million to fund research and match state investments in psychedelic programs. Interagency collaboration among FDA, DEA, HHS, and Veterans Affairs boosts clinical trials and evidence generation. The Attorney General must initiate rescheduling reviews after successful Phase 3 trials.

Trump emphasized veteran suicide rates, noting psychedelics’ potential for PTSD and depression. Commissioner Makary affirmed quick decisions without compromising science or safety. Applications are arriving at FDA amid urgent mental health needs. This combines regulatory tools to cut bureaucracy while upholding oversight.

Historical Shift from Drug War Era

Psychedelics like LSD, ecstasy, and ibogaine faced Schedule I classification since the 1960s-70s, deemed without medical use. Recent FDA Breakthrough Therapy designations reflect clinical trial successes for severe conditions. Veterans’ groups and professionals pushed for change amid rising suicides. State initiatives preceded federal action. Trump’s order marks the first major executive push for expedited review, legitimizing research stifled by past policies.

Trump Signs Psychedelics Order https://t.co/Iva6TdQYaN via @reason

— Boomertarian Norm (@BoomertarianN) April 21, 2026

Americans across political lines share frustration with government failures blocking innovative solutions. This order prioritizes patients over entrenched regulations, echoing demands for limited government focused on real results. Conservatives see victory in America First innovation reducing veteran suffering; even skeptics recognize urgency when elites prioritize control over lives.

Expected Impacts on Patients and Veterans

Short-term, three compounds enter fast-track review, with Right to Try access for desperate patients. Clinical trial participation rises immediately. Long-term, successful trials could reschedule drugs, spawn therapy clinics, and set precedents for therapies. Veterans gain priority for PTSD treatments showing rapid symptom relief in studies. Biotech firms and researchers access new funding. States partner via matching grants.